These results suggested that GA-amide might inhibit glioma growth by modulating the cytoskeletal proteins that interact with WDR1; thus, we evaluated changes in the cytoskeleton and globular actin (G-actin)/microfilament (F-actin) expression after GA-amide treatment in T2-4 cells. The gene discussed is WDR1; the disease is central nervous system cancer.